CorMedix Inc. (NYSEAMERICAN: CRMD) is falling hard in the market this morning. However, with no negative news hitting the wire, many are wondering the reason for the fall and whether or not buying now is simply a discounted opportunity for future gains. Today, we’ll talk about:
- Why today’s dip in CRMD stock values could be an opportunity;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
Why CRMD May Be A Big Opportunity
As mentioned above, CorMedix isn’t having the best of days in the market today. Unfortunately, with no news released by the company and nothing hitting the media wire elsewhere, the reason for the gains is hard to pin down.
Nonetheless, this may be a great opportunity. The truth of the matter is that there’s good reason to be excited about CRMD for the long run. The company’s flagship candidate, Neutrolin, may be one of incredibly high value.
Neutrolin is a catheter lock solution. The solution has been shown to produce overwhelmingly positive results in various clinical trials to date. The data shows that Neutrolin is efffective in the prevention of infections associated with intravenous catheters.
This could prove to be a very valuable product. After all, the venous catheter market is a massive one and is growing quickly. At the moment, the compound annual growth rate of the market sits at above 5%. Moreover, it is estimated that the market will grow to be worth $1 billion annually, relatively soon.
With that considered, should Neutrolin continue to produce positive results and receive regulatory approval, the CRMD could be sitting on a figurative gold mine. Considering that multiple clinical trials have proven a redduction of risk of catheter-related infections.
While there are already options on the market that are used regularly in the space, study data suggests that Neutrolin could be the superior option.
It’s also worth looking at the stock chart over the past six months. While we’ve seen plenty of peaks and valleys, the overall trend on the stock has been up. With positive clinical data, strong IP, and many coming catalysts to support the continued growth, CRMD may see an incredible rise in value ahead.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the movement in the market tends to happen through a series of peaks and valleys. Of course, buying in the valleys is where investors have the largest opportunity to see profits.
In the case of Cormedix, it seems as though today’s movement is leading to an opportunity. As is just about always the case, our partners at Trade Ideas were the first to alert us to the declines. Currently (11:33), CRMD is trading at $1.66 per share after a loss of $0.17 per share or 9.07% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CRMD. In particular, we’ll continue to follow the story surrounding the company’s work to bring Neutrolin to market. Nonetheless, we’ll keep an eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!